Listerine meeting postponed
This article was originally published in The Tan Sheet
Executive Summary
"Feedback" meeting on Pfizer's proposed changes to the OTC anticaries final monograph, originally slated for June 18, will be rescheduled within a month to give Division of OTC Drug Products more time to review relevant material, FDA says June 14. Meeting is part of Pfizer's efforts to amend monograph to allow for a mouthrinse combining essential oils, sodium fluoride (1"The Tan Sheet" June 10, 2002, p. 3)...
You may also be interested in...
Listerine With Fluoride Proposed Six-Month Study To Be Reviewed By FDA
Pfizer Consumer Healthcare plans to conduct a six-month clinical study involving at least 300 subjects to determine whether adding .02% sodium fluoride to the company's Listerine mouthrinse affects the antiplaque/ antigingivitis effectiveness of the product
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.